Hikma is not resting on its laurels after paying $375m upfront for US injectables specialist Custopharm two years ago, penning another acquisition agreement for a bundle of pharma and physical assets from Danish firm Xellia.
Hikma is continuing to beef up its major injectables business, striking a deal worth up to $185m to bring on board a collection of assets from Xellia in the US, including a portfolio of products, a US manufacturing facility, and an R&D center in Croatia.
Subject to US Federal Trade Commission approval, the deal will add significant scale to Hikma’s US operations, enhance its US...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
